Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
kio-101 save search
Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Published: 2024-04-08 (Crawled : 22:00) - biospace.com/
BPTS | $10.15 3.36% 3.25% 3.7K
|
Manufacturing
|
| O: -3.31%
H: 0.0%
C: -4.69%
bio101 obesity study
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye
Published: 2024-03-08 (Crawled : 14:30) - biospace.com/
KPRX | $0.504 -13.03% -14.98% 290K
|
Manufacturing
|
| O: 2.4%
H: 2.64%
C: -4.18%
kio-101 publication treatment eye study
Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis
Published: 2023-08-23 (Crawled : 16:00) - biospace.com/
KPRX | $0.504 -13.03% -14.98% 290K
|
Manufacturing
|
| O: 19.61%
H: 6.56%
C: 2.46%
kio-100 ocular granted treatment pharmaceuticals family
Kiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseases
Published: 2023-04-17 (Crawled : 15:00) - biospace.com/
KPRX | $0.504 -13.03% -14.98% 290K
|
Manufacturing
|
| O: -1.25%
H: 0.0%
C: -1.22%
kio-101 ocular presentation treatment pharmaceuticals trial phase 2
Biophytis Announces the Signature of a Master Service Agreement With Intsel Chimos, a Pharmaceutical Company That Will Operate Sarconeos (BIO101) in France for the Treatment of Severe Forms of COVID-19
Published: 2023-03-02 (Crawled : 08:00) - biospace.com/
BPTS | $10.15 3.36% 3.25% 3.7K
|
Manufacturing
|
| O: 27.59%
H: 22.0%
C: 10.59%
bio101 covid-19 treatment service agreement
Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases
Published: 2023-02-07 (Crawled : 15:00) - biospace.com/
KPRX | $0.504 -13.03% -14.98% 290K
|
Manufacturing
|
| O: 64.63%
H: 9.07%
C: -15.74%
kio-101 treatment pharmaceuticals drug ocular approval presentation study
Kiora Pharmaceuticals Announces Publication of Phase 1 Trial Results for KIO-100 as a Treatment for Ocular Inflammatory Disease
Published: 2022-10-17 (Crawled : 15:00) - biospace.com/
KPRX | $0.504 -13.03% -14.98% 290K
|
Manufacturing
|
| O: 4.71%
H: 0.0%
C: -4.5%
kio-100 treatment pharmaceuticals disease ocular trial publication phase 1
Kiora Pharmaceuticals Announces Presentation of KIO-101 Clinical Trial Data at the American Society of Cataract and Refractive Surgery 2022
Published: 2022-04-25 (Crawled : 15:00) - biospace.com/
KPRX | $0.504 -13.03% -14.98% 290K
|
Manufacturing
|
| O: 5.79%
H: 0.0%
C: -8.46%
kio-101 trial presentation
Biophytis: Biophytis Presents Sarconeos (BIO101) Development Program in Sarcopenia at the 12th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston April 20-22, 2022
Published: 2022-04-19 (Crawled : 11:00) - biospace.com/
BPTS | $10.15 3.36% 3.25% 3.7K
|
Manufacturing
|
| O: -7.71%
H: 7.25%
C: 2.81%
bio101 research conference program international
Biophytis Provides Updates on Sarconeos (BIO101) Clinical Development
Published: 2022-04-07 (Crawled : 09:00) - biospace.com/
BPTS | $10.15 3.36% 3.25% 3.7K
|
Manufacturing
|
| O: -15.08%
H: 4.61%
C: -2.57%
bio101
Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease
Published: 2021-12-14 (Crawled : 12:00) - eyegatepharma.com
KPRX | $0.504 -13.03% -14.98% 290K
|
Manufacturing
|
| O: -8.7%
H: 0.0%
C: 0.0%
kio-101 dry eye phase 2 eye eye disease disease topline
Biophytis to Host Virtual KOL Event on Sarconeos (BIO101) on its Lead Projects in COVID-19 and Sarcopenia
Published: 2021-10-06 (Crawled : 07:00) - globenewswire.com
BPTS | $10.15 3.36% 3.25% 3.7K
|
Manufacturing
| Email alert
Add to watchlist
covid
Biophytis Announces Promising Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021
Published: 2021-10-04 (Crawled : 07:00) - globenewswire.com
BPTS | $10.15 3.36% 3.25% 3.7K
|
Manufacturing
| Email alert
Add to watchlist
phase 2 results phase 2b research trial conference
Biophytis to Present Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021
Published: 2021-09-29 (Crawled : 06:00) - globenewswire.com
BPTS | $10.15 3.36% 3.25% 3.7K
|
Manufacturing
| Email alert
Add to watchlist
phase 2 results phase 2b research trial conference
Biophytis Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 COVA Study With Sarconeos (BIO101) in COVID-19
Published: 2021-09-15 (Crawled : 07:00) - globenewswire.com
BPTS | $10.15 3.36% 3.25% 3.7K
|
Manufacturing
| Email alert
Add to watchlist
phase 2 covid phase 2/3 results
Biophytis Receives Favorable Recommendation From Data Monitoring Committee (DMC) Based on Safety Analysis of Sarconeos (BIO101) to Continue Patient Recruitment in the COVA Study in COVID-19
Published: 2021-08-16 (Crawled : 06:00) - globenewswire.com
BPTS | $10.15 3.36% 3.25% 3.7K
|
Manufacturing
| Email alert
Add to watchlist
covid
Biophytis Announces Top Line Results of SARA-INT Phase 2 Study With Sarconeos (BIO101) in Sarcopenia
Published: 2021-08-02 (Crawled : 07:00) - globenewswire.com
BPTS | $10.15 3.36% 3.25% 3.7K
|
Manufacturing
| Email alert
Add to watchlist
topline phase 2 results
Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021
Published: 2021-07-12 (Crawled : 07:00) - globenewswire.com
BPTS | $10.15 3.36% 3.25% 3.7K
|
Manufacturing
| Email alert
Add to watchlist
positive covid preclinical covid-19 pre-clinical
Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021
Published: 2021-06-30 (Crawled : 21:00) - globenewswire.com
BPTS | $10.15 3.36% 3.25% 3.7K
|
Manufacturing
| Email alert
Add to watchlist
phase 2 results trial
Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study
Published: 2021-06-30 (Crawled : 21:00) - globenewswire.com
BPTS | $10.15 3.36% 3.25% 3.7K
|
Manufacturing
| Email alert
Add to watchlist
phase 2 covid milestone
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.